What is the long-term trend for Adaptive Biotechnologies's long-term marketable securities?

Over 3 years (2020 to 2025), Adaptive Biotechnologies's long-term marketable securities has grown at a -51.8% compound annual growth rate (CAGR), from $118.53M to $13.23M.

Adaptive Biotechnologies ADPT Long-term marketable securities

Long-term marketable securities at other companies

Nektar TherapeuticsNKTR

——

Other financials

Income statement

See full

Revenue$70.9M+35.1%

Gross profit$52.2M+47.1%

Operating income-$19.2M+35.1%

Net income-$20.0M+32.9%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$77.6M+53.2%

Total debt$208.2M-5.6%

Total equity$216.3M+13.6%

Total assets$505.9M-1.0%

Cash flow

See full

Operating cash flow-$9.5M+66.5%

CapEx$796.0K-36.8%

Free cash flow-$10.3M+65.3%

Valuation

See full

Market cap$2.76B+93.6%

Enterprise value$2.89B+78.0%

P/S9.3×+1.8×

Profitability

See full

Gross margin75.3%+12.7pp

Operating margin-15.8%-7.0pp

Net margin-16.8%-7.3pp

FCF margin-10.5%-4.6pp

Returns & leverage

See full

Return on equity-24.4%-9.2pp

Debt / equity1×-0.2×

Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's long-term marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Adaptive Biotechnologies's long-term marketable securities?: Adaptive Biotechnologies (ADPT) reported long-term marketable securities of $18.89M in Q1 2026.
How has Adaptive Biotechnologies's long-term marketable securities changed year-over-year?: Adaptive Biotechnologies's long-term marketable securities decreased by 52.0% year-over-year, from $39.36M to $18.89M.
What is the long-term trend for Adaptive Biotechnologies's long-term marketable securities?: Over 3 years (2020 to 2025), Adaptive Biotechnologies's long-term marketable securities has grown at a -51.8% compound annual growth rate (CAGR), from $118.53M to $13.23M.